Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis

Hepatology International

Volumn 6, Issue 2, 2012, Pages 475-481

  Rowell, J ^a   Thompson, A J ^b   Guyton, J R ^a   Lao, X Q ^c   McHutchison, J G ^b   McCarthy, J J ^c   Patel, K ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Apolipoprotein AI; Apolipoprotein C III; Fibrosis; Hepatitis C virus

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; UNIVARIATE ANALYSIS; VIRAL CLEARANCE;

EID: 84862897538     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9291-x     Document Type: Article

References (34)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567
2. Alaei M, Negro F. Hepatitis C virus and glucose and lipid metabolism. Diabetes Metab 2008;34:692-700
3. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viralrelated steatosis. Faseb J 2002;16:185-194
4. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010;21:33-40
5. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001;34:428-434
6. Petit JM, Benichou M, Duvillard L, et al. Hepatitis C virusassociated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 2003; 98:1150-1154
7. Sud A, Hui JM, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004;39:1239-1247
8. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-992
9. Bochud PY, Cai T, Overbeck K. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2002;51:655-666
10. Negro F, Clement S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009;16:681-688
11. Jhaveri R, McHutchison J, Patel K, Qiang G, Diehl AM. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis 2008;197:283-291
12. Molina S, Misse D, Roche S, et al. Identification of apolipoprotein C-III as a potential plasmatic biomarker associated with the resolution of hepatitis C virus infection. Proteomics Clin Appl 2008;2:751-761
13. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20
14. Zheng C, Khoo C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 2007;48:1190-1203
15. Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb 2009;16:6-11
16. Huang H, Sun F, Owen DM, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007;104: 5848-5853
17. Olofsson SO, Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005; 258:395-410
18. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009;205:1-8
19. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008;114:611-624
20. Tanaka N, Moriya K, Kiyosawa K, Koike K, Aoyama T. Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice: implications for HCV-associated hepatocarcinogenesis. Int J Cancer 2008;122:124-131
21. Nguyen H, Sankaran S, Dandekar S. Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. Virology 2006;354:58-68
22. Lacorte JM, Ktistaki E, Beigneux A, Zannis VI, Chambaz J, Talianidis I. Activation of CAAT enhancer-binding protein delta (C/EBPdelta) by interleukin-1 negatively influences apolipoprotein C-III expression. J Biol Chem 1997;272:23578-23584
23. Lacorte JM, Beigneux A, Parant M, Chambaz J. Repression of apoC-III gene expression by TNFalpha involves C/EBPdelta/NFIL6beta via an IL-1 independent pathway. FEBS Lett 1997;415: 217-220
24. Kardassis D, Pardali K, Zannis VI. SMAD proteins transactivate the human ApoCIII promoter by interacting physically and functionally with hepatocyte nuclear factor 4. J Biol Chem 2000; 275:41405-41414
25. Fernandez-Miranda C, Castellano G, Guijarro C, et al. Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha. Am J Gastroenterol 1998;93:1901-1904
26. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am J Gastroenterol 2001;96:2468-2472
27. Andrade RJ, Garcia-Escano MD, Valdivielso P, Alcantara R, Sanchez-Chaparro MA, Gonzalez-Santos P. Effects of interferonbeta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. Aliment Pharmacol Ther 2000;14:929-935
28. Andre P, Komurian-Pradel F, Deforges S, et al. Characterization of low-and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002;76:6919-6928
29. Nitanai A, Katoh N, Oikawa S, et al. Decreases in serum apolipoprotein C-III concentration in cows with ethionine-induced fatty liver. J Vet Med Sci 2004;66:1113-1118
30. Quarfordt SH, Shelburne FA, Meyers W, Jakoi L, Hanks J. Effect of apolipoproteins on the induction of hepatic steatosis in rats. Gastroenterology 1981;80:149-153
31. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357: 1069-1075
32. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006;43:S113-S120
33. Barr SI, Kottke BA, Mao SJ. Postprandial exchange of apolipoprotein C-III between plasma lipoproteins. Am J Clin Nutr 1981;34:191-198
34. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting ipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118:2047-2056